Full Press Release Details
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options
If you purchased or acquired MoonLake Immunotherapeutics common stock between March 10, 2024 through September 29, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ:MLTX) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired MoonLake Immunotherapeutics common stock between March 10, 2024 through September 29, 2025, both dates inclusive (the “Class Period”).
Investors have until December 15, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The suit alleges that MoonLake Immunotherapeutics misled investors about its sole drug candidate, sonelokimab (SLK), which was promoted as superior to competing monoclonal antibodies. The complaint claims MoonLake and its executives repeatedly touted SLK’s Nanobody structure as providing unique clinical advantages, while failing to disclose that it targeted the same molecules as UCB’s BIMZELX and offered no proven superiority. On September 28, 2025, MoonLake announced Phase 3 results showing SLK failed to match BIMZELX’s efficacy, which analysts called a “disastrous result.” Following the news, MoonLake’s stock collapsed nearly 90%, causing significant losses for investors.
On September 29, 2025, before the market opened, MoonLake Immunotherapeutics filed with the SEC a current report on Form 8-K. Attached to the current report was a press release which stated that, in MoonLake’s VELA-2 trial, “intercurrent events in the higher-than-expected placebo arm precluded the study from achieving statistical significance in the week 16 primary endpoint using the composite strategy[.]”
On this news, MoonLake stock plummeted 89.9% on September 29, 2025.
If you purchased or otherwise acquired MoonLake shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Tags
MoonLake Immunotherapeutics
Bragar Eagel & Squire